Wheatland Advisors Inc. raised its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 0.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,250 shares of the pharmaceutical company’s stock after buying an additional 2 shares during the period. Wheatland Advisors Inc.’s holdings in GlaxoSmithKline PLC were worth $787,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Bronfman E.L. Rothschild L.P. raised its stake in shares of GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after buying an additional 753 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 2,359 shares in the last quarter. Proficio Capital Partners LLC raised its stake in shares of GlaxoSmithKline PLC by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after buying an additional 1,990 shares in the last quarter. Heritage Trust Co acquired a new stake in shares of GlaxoSmithKline PLC during the first quarter worth $123,000. Finally, Westwood Holdings Group Inc. raised its stake in shares of GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after buying an additional 400 shares in the last quarter. 8.96% of the stock is currently owned by institutional investors.

Shares of GlaxoSmithKline PLC (GSK) opened at 39.53 on Thursday. The stock’s 50 day moving average price is $42.13 and its 200-day moving average price is $41.86. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.59. The firm has a market capitalization of $96.61 billion, a P/E ratio of 38.23 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last released its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The company had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. On average, equities analysts expect that GlaxoSmithKline PLC will post $2.85 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be given a $0.491 dividend. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 4.97%. GlaxoSmithKline PLC’s dividend payout ratio is presently 194.00%.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/10/wheatland-advisors-inc-has-787000-position-in-glaxosmithkline-plc-nysegsk.html.

A number of equities research analysts have weighed in on the company. Citigroup Inc. reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, July 27th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Wednesday, May 31st. TheStreet lowered GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a report on Wednesday, July 26th. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a report on Tuesday, July 18th. Finally, Berenberg Bank raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $46.00.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.